Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

Clinical trial NCT00050232 · COMPLETED

Trial details

NCT number: NCT00050232
Sponsor: Avanir Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Sclerosis

Start date: 2002-12-01
Primary completion: 2004-06-01
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.